Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?

CSL (ASX:CSL) is in focus after releasing its full year 2026 results, issuing earnings guidance for 2027, and declaring a US$1.62 per share dividend. This combination gives investors several fresh data points to assess.

The CSL share price has reacted sharply around these results, with a 30 day share price return of 45.48% and a 90 day share price return of 79.98% taking it to A$173.88, even though the 1 year total shareholder return is still down 16.24% and the 5 year total shareholder return is down 38.52%. This recent upswing suggests investor sentiment has improved following the 2026 earnings release, 2027 guidance and the new dividend, although longer term holders are still carrying meaningful drawdowns.

Scan how CSL’s sharp move compares with other high quality companies on the move by checking our hand picked list of 12 high quality undiscovered gems.

CSL has just swung from profit to loss while the share price has run hard. Is it more sensible to accept today’s reset valuation, or to wait and see what the current guidance and dividend imply for a better entry point?

Most Popular Narrative: 17.2% Undervalued

According to the most followed narrative on CSL, a fair value of A$210.00 compares to the current A$173.88 share price. That gap is what the thesis tries to explain.

CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation. Healthcare demand tends to remain resilient regardless of economic conditions.

Read the complete narrative.

Want to understand why this narrative sees CSL as undervalued? The model leans on steady revenue expansion, firmer profit margins and a premium future earnings multiple. Curious which assumptions really move that A$210.00 figure? The full narrative breaks down how those pieces fit together.

Result: Fair Value of A$210.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CSL still carries clear risks, including its recent net loss of $2,579.0m and reliance on successful product development and regulatory approvals to support the current thesis.

Find out about the key risks to this CSL narrative.

Next Steps

Given the mix of optimism and concern around CSL in this article, it makes sense to move quickly and test the numbers yourself. To see both sides of the story in one place, check the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CSL?

If the recent CSL moves have sharpened your focus, now is the moment to broaden your watchlist with other opportunities before the next wave of interest arrives.

• Target potential mispricings by reviewing companies on our hand picked list of 13 high quality undervalued stocks.
• Strengthen your income stream by scanning businesses on the 8 dividend fortresses that already offer substantial yields.
• Dial down risk in your portfolio by checking stocks highlighted in the 12 resilient stocks with low risk scores while others are still overlooking them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com